49 results about "Interferon regulatory factors" patented technology

This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and / or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and / or FLJ43663 polypeptides in T-cell lymphoma cells are provided.

The invention discloses the function of IRF 9 in stent and carotid endarterectomy restenosis as well as an application of an inhibitor of IRF9, belonging to the field of the function and the application of a gene. According to the invention, IRF9 gene knockout mice and wild C57 mice are taken as experimental subjects, detection of mouse intima neogenesis, vascular wall cell proliferation level and smooth muscle cell phenotype is performed through a vascular injury model, and the results show that IRF9 gene knockout mice represents inhibited intima neogenesis and cell proliferation in comparison with the wild C57 mice. The invention discloses the function of the IRF9 gene in the stent and carotid endarterectomy restenosis, which mainly shows that the IRF9 gene has the function of promoting the intima neogenesis and cell proliferation. According to the abovementioned function, the IRF9 can be used as a drug target for screening drugs for treating hemadostenosis diseases, and the inhibitor of the IRF9 can be used for preparing the drug for treating the stent and carotid endarterectomy restenosis.

This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and / or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and / or FLJ43663 polypeptides in T-cell lymphoma cells are provided.

The invention discloses the function of an IRF3 gene in atherosclerosis and an application of an inhibitor of the IRF3 gene, belonging to the field of the function and the application of a gene. According to the invention, ApoE- / -mice and IRF3- / -ApoE- / -mice are taken as experimental subjects, an atherosclerosis model is obtained through high-fat induction, AS model mouse plaque area measurement and inclusion analysis are performed, and the results show that the aorta plaque area of the IRF3- / -ApoE- / -mice is remarkably reduced in comparison with that of the ApoE- / -mice. The invention discloses the function of the IRF3 gene in an atherosclerosis disease, which means that the IRF3 gene has an effect of promoting the formation of the aorta plaques, especially that the IRF3 gene can worsen the atherosclerosis. According to the abovementioned function, the IRF3 can be used as a drug target for screening drugs for treating the atherosclerosis disease. The inhibitor of the IRF3 can be used for preparing the drug for treating the atherosclerosis disease.

The invention discloses the function of an IRF3 gene in atherosclerosis and an application of an inhibitor of the IRF3 gene, belonging to the field of the function and the application of a gene. According to the invention, ApoE- / -mice and IRF3- / -ApoE- / -mice are taken as experimental subjects, an atherosclerosis model is obtained through high-fat induction, AS model mouse plaque area measurement and inclusion analysis are performed, and the results show that the aorta plaque area of the IRF3- / -ApoE- / -mice is remarkably reduced in comparison with that of the ApoE- / -mice. The invention discloses the function of the IRF3 gene in an atherosclerosis disease, which means that the IRF3 gene has an effect of promoting the formation of the aorta plaques, especially that the IRF3 gene can worsen the atherosclerosis. According to the abovementioned function, the IRF3 can be used as a drug target for screening drugs for treating the atherosclerosis disease. The inhibitor of the IRF3 can be used for preparing the drug for treating the atherosclerosis disease.

The invention discloses application of interferon regulatory factor 4 (IRF4) gene in coronary atherosclerotic heart disease, belonging to the field of gene functions and applications. According to the application, IRF4 gene knockout mice and heart-specific IRF4 transgenic mice are taken as experimental subjects, and myocardial infarction model is constructed by blocking mouse heart left anterior descending coronary artery (LAD); results show that compared with a-MHC-Cre moue, the myocardial infarction area, myocardial hypertrophy and myocardial fibrosis degree of the IRF4 gene knockout mouse are remarkably increased, while the heart function of the heart-specific IRF4 transgenic mouse is remarkably improved. Therefore, the function of IRF4 gene in coronary atherosclerotic heart disease is mainly reflected in the protective effect of IRF4 gene on coronary atherosclerotic heart disease. Relative to the function of IRF4, the invention provides application of IRF4 in preparation of medicaments for treating coronary atherosclerotic heart disease.

The invention discloses a larimichthys crocea interferon regulatory factor IRF3 starter, a nucleic acid builder, a cell and a preparing method and application of the larimichthys crocea interferon regulatory factor IRF3 starter, the nucleic acid builder and the cell. The nucleotide sequence of the larimichthys crocea interferon regulatory factor IRF3 starter is shown as Seq ID No.1 or a nucleotide sequence complementary to Seq ID No.1. The invention further protects application of the starter or the nucleic acid builder or a carrier or a reconstitution cell or fish or a mammal containing the starter or the nucleic acid builder or the carrier or the reconstitution cell in regulating target gene expression or transgenic fish.

The invention discloses a larimichthys crocea interferon regulatory factor IRF7 starter, a nucleic acid builder, a cell and a preparing method and application of the larimichthys crocea interferon regulatory factor IRF7 starter, the nucleic acid builder and the cell. The nucleotide sequence of the larimichthys crocea interferon regulatory factor IRF7 starter is shown as Seq ID No.1 or a nucleotide sequence complementary to Seq ID No.1. The invention further protects application of the starter or the nucleic acid builder or a carrier or a reconstitution cell or fish or a mammal containing the starter or the nucleic acid builder or the carrier or the reconstitution cell in regulating target gene expression or transgenic fish.

The present disclosure provides compositions and methods for inhibiting hepatitis B virus (HBV) in infected cells. Exemplary methods include contacting an infected cell with one or more agents that induce interferon regulatory factor 3 (IRF3) activation in the infected cell. In some embodiments, one or more agents include a nucleic acid molecule comprising a pathogen-related molecular pattern (PAMP), a small molecule agent (e.g., a benzothiazole derivative molecule), or a combination thereof. In some embodiments, the method further comprises contacting the infected cells with an NRTI. The method may be an in vivo method of treating a subject suffering from HBV infection comprising administering a therapeutically related amount of one or more agents formulated in one or more therapeutically effective compositions. An exemplary composition is formulated for treating hepatitis B virus (HBV) infection in a subject, comprising a RIG-I agonist, a vehicle for intracellular delivery, and a pharmaceutically acceptable carrier.

The invention discloses a function and application of an interferon regulatory factor 4 (IRF4) in scaffold and endarterectomy restenosis, belonging to the field of gene functions and applications. According to the application disclosed by the invention, IRF4 gene knockout mice and mild C57 mice are taken as experimental subjects, and a vascular injury model is adopted to carry out neointima formation determination, vascular wall cell proliferation level detection and smooth muscle cell phenotype detection of a vascular injury model mouse; results show that compared with the mild mouse, the IRF4 gene knockout mouse has more distinct neointima formation and cell proliferation, which indicates that the function of the IRF4 gene in scaffold and endarterectomy restenosis is manifested by that the IRF4 gene has effect of inhibiting restenosis caused by vascular injury, especially protecting scaffold and endarterectomy restenosis. As for the function of IRF4, the IRF4 can be used for preparing medicaments for treating angiostenosis, especially medicaments for treating scaffold and endarterectomy restenosis.

The invention discloses an application of an interferon regulatory factor 5(IRF5) and an inhibitor thereof in treating cardiac hypertrophy, and belongs to the filed of function and application of genes. The application of the interferon regulatory factor 5(IRF5) and the inhibitor thereof in treating cardiac hypertrophy determines the relationships between the expression of IRF5 genes and cardiac hypertrophy disease. The relationships are inhibiting the expression of the IRF5 genes, accordingly remarkably inhibiting cardiac hypertrophy and fibrosis, and improving cardiac function; promoting the expression of the IRF5 genes, accordingly remarkably promoting cardiac hypertrophy and fibrosis, and deteriorating cardiac function. Thereby, IRF5 can be adopted as a drug target used for screening drugs which protect cardiac function, prevent, relieve and / or treat cardiac hypertrophy and resist myocardial fibrosis. The inhibitor of IRF5 can be used for preparing drugs which protect cardiac function, prevent, relieve and / or treat cardiac hypertrophy and resist myocardial fibrosis.

Provided are: a composition for diagnosing non-diabetic angiostenosis, containing a preparation measuring the level of one or more proteins selected from the group consisting of poly (ADP-ribose) polymerase 4 (PARP4), vitamin D-binding protein (VDB), and laminin subunit beta-1 (LAMB1); a composition for diagnosing diabetic angiostenosis, containing a preparation measuring the level of one or more proteins selected from the group consisting of interferon regulatory factor 7 (IRF7), a dedicator of cytokinesis protein 2 (DOCK2), and a hemoglobin subunit beta (HBB); a kit for diagnosing angiostenosis, containing the composition for diagnosing diabetic angiostenosis; a method for providing information for diagnosing non-diabetic angiostenosis; and a method for providing information for diagnosing non-diabetic angiostenosis. The present invention provides a composition for diagnosing angiostenosis, so as to measure and compare the changing protein expression levels in non-diabetic or diabetic angiostenosis patients, thereby enabling early diagnosis of angiostenosis and a meaningful prediction or an identification of the degree of the disease. In addition, the diagnostic composition of the present invention enables non-invasive diagnosis, thereby enabling simple and valid early stage diagnosis of angiostenosis by using blood and urine testing and the like.

The invention provides a bicistronic DNA vaccine for grouper viral neuronecrosis, which is a recombinant eukaryotic expression vector, and the recombinant eukaryotic expression vector can simultaneously express the P-domain of neuronecrosis virus capsid protein and the superfamily domain of the grouper interferon regulatory factor 3 protein. The anti-necrosis virus bicistronic DNA vaccine prepared by the invention can well express the neuronecrosis virus capsid protein P-domain and the superfamily domain of the host's interferon regulatory factor 3 protein when transfected into fish. The prepared anti-neuronecrosis virus bicistronic DNA vaccine enhances the ability of fish to resist nerve necrosis virus infection, reduces the mortality rate of fish infected with the virus, enhances the humoral immunity of fish caused by the vaccine, and causes fish body The comprehensive immune response provides a good immune protection effect for the fish body.

The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.

The invention discloses interferon regulatory factor 9 (IRF9) and application of an inhibitor thereof in cerebral apoplexy, belonging to the field of gene function and application. The invention uses IRF9 gene knock-out mice and brain-specific IRF9 transgenic mice as experimental subjects and adopts middle cerebral artery ischemia reperfusion model, results show that compared with mild type C57 mouse, the brain infarction volume of IRF9 gene knock-out mouse is apparently inhibited, and nerve function is improve remarkably, while the infarction volume of nerve-specific IRF9 transgenic mouse is apparently inhibited, and nerve function is deteriorated markedly. Therefore, IRF9 gene has nervous system function deterioration effect; especially, IRF9 gene can deteriorate cerebral apoplexy. As for the above function of IRF9, the invention provides application of IRF9 as drug target of cerebral apoplexy treatment in developing medicaments for treating cerebral apoplexy.